EGFR inhibition mimics the dual inhibition of MEK/ERK, effectively targets JunD/RSK3 and reverses the BETi resistance phenotype, again highlighting the potential of anti-EGFR therapies in treating BET-inhibition-resistant tumours. Here, JUND is linked to neoplasm.